Lobbying Filing Details

Total Spending

$2,440,000

Activities

5

Lobbyists

12

Gov't Entities

14

Filing Information
Filing UUID:
e2da4764-9942-4a58-bb71-5df6a3fc754f
Type:
Q2 - 2nd Quarter - Report
Period:
2026 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 20, 2026 at 8:02 PM
Income:
$0
Expenses:
$2,440,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Jesse Kerns
Registrant
AMGEN, INC.
WASHINGTON, District of Columbia
Client
AMGEN INC
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Copyright/Patent/Trademark

Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Lobbyists (5)
  • GREGORY PORTNER
  • WILLIAM O'BRIEN
  • HELEN RHEE
  • MRS. JORDAN LYNN LAYSON
  • CHASE THOMAS
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act

Lobbyists (12)
  • GREGORY PORTNER
  • JESSE KERNS
  • HOWARD MOON
  • L NICOLE CURRIE
  • WILLIAM O'BRIEN
  • HELEN RHEE
  • RUTH HOFFMAN
  • MRS. JORDAN LYNN LAYSON
  • MS. KIMBERLY LOVE
  • MR. MATTHEW MCMURRAY
  • CHAD PETTIT
  • CHASE THOMAS
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Health & Human Services, Dept of (HHS)
Activity 3
Medicare/Medicaid

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act

Lobbyists (12)
  • GREGORY PORTNER
  • JESSE KERNS
  • HOWARD MOON
  • L NICOLE CURRIE
  • WILLIAM O'BRIEN
  • HELEN RHEE
  • RUTH HOFFMAN
  • MRS. JORDAN LYNN LAYSON
  • MS. KIMBERLY LOVE
  • MR. MATTHEW MCMURRAY
  • CHAD PETTIT
  • CHASE THOMAS
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Health & Human Services, Dept of (HHS)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 4
Tariff (miscellaneous tariff bills)

Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025

Lobbyists (10)
  • GREGORY PORTNER
  • JESSE KERNS
  • HOWARD MOON
  • L NICOLE CURRIE
  • WILLIAM O'BRIEN
  • HELEN RHEE
  • MRS. JORDAN LYNN LAYSON
  • MS. KIMBERLY LOVE
  • MR. MATTHEW MCMURRAY
  • CHASE THOMAS
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 5
Taxation/Internal Revenue Code

Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income

Lobbyists (4)
  • GREGORY PORTNER
  • L NICOLE CURRIE
  • WILLIAM O'BRIEN
  • CHASE THOMAS
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Treasury, Dept of

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.